The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | Doxycycline/TUDCA versus standard supportive therapy in transthyretin cardiac amyloidosis
Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, discusses a Phase III study (NCT03481972) which compared doxycycline and tauroursodeoxycholic acid (TUDCA) versus standard supportive therapy alone in transthyretin (ATTR) cardiac amyloidosis. The trial found that doxycycline did not improve survival in patients with wild-type ATTR amyloidosis. Despite the negative outcome, the study provides valuable insights into the natural history of this disease. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Pfizer, Jannsen-Cilag
Membership on Board of Directors or advisory committee: Jannsen-Cilag, Siemens
